VIARTIS

 

PARKINSON'S DISEASE

 

 

 

 

 

 

PARKINSON'S DISEASE NEWS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SEPTEMBER 2015

 

29th September  2015 - New book

10 BREAKTHROUGH THERAPIES FOR PARKINSON'S DISEASE

Michael S.Okun

 CLICK HERE FOR A PRINTABLE OR WHITE BACKGROUND VERSION OF THIS ARTICLE

Publishers description : In his latest book, Dr Okun he reveals the breakthroughs in Parkinsonís disease that will pave the road to meaningful progress. In this book he reviews all of the recent breakthrough ideas and therapies in Parkinsonís disease, and he reviews the knowledge gained which is extending far beyond a single drug or stem cell. He paints the broader and more exciting picture and reviews the portfolio of breakthroughs spanning drug, cell, vaccine, device, genetics, care, and behavior. He believes that patients and families with personal investments in Parkinsonís disease should be informed and updated about all of these potential breakthrough therapies. Click here for more details For more books concerning Parkinson's Disease go to Parkinson's Disease books In order to refer to this article on its own click here

 

24th September 2015 - New research

AUTOANTIBODIES FOR THE DIAGNOSIS OF PARKINSON'S DISEASE

 CLICK HERE FOR A PRINTABLE OR WHITE BACKGROUND VERSION OF THIS ARTICLE

For the first time a selection of blood-borne autoantibody biomarkers with a higher prevalence in early Parkinson's Disease were used to facilitate the diagnosis of early Parkinson's Disease. Antibodies are proteins produced by a person's immune system that allows their body to distinguish between "self" and "non-self" proteins. For more information go to : Autoantibodies

The sera of people with early stage Parkinson's Disease were screened with human protein microarrays containing 9486 potential antigen targets in order to identify autoantibodies that are potentially useful as biomarkers for Parkinson's Disease.

Selected, blood-borne autoantibody biomarkers with a higher prevalence in early Parkinson's Disease could distinguish early Parkinson's Disease with an overall accuracy of 88%, a sensitivity of 94% and a specificity of 85%.

These biomarkers were also capable of differentiating people with early Parkinson's Disease from those with mild to moderate Parkinson's Disease with an overall accuracy of 97%. The biomarkers could also distinguish people with early Parkinson's Disease from those with other neurological disorders.

The results demonstrate, for the first time, that selected autoantibodies may prove to be useful as effective blood-based biomarkers for the diagnosis of early Parkinson's Disease.

Reference : Immunology Letters [2015] Sep 16 [Epub ahead of print] (C.A.DeMarshall, M.Han, E.P.Nagele, A.Sarkar, N.K.Acharya, G.Godsey, E.L.Goldwaser, M.Kosciuk, U.Thayasivam, B.Belinka, R.G.Nagele) Complete abstract  In order to refer to this article on its own click here     

 

19th September 2015 - New research

LONG TERM EFFECTS OF DBS ON PARKINSON'S DISEASE

 CLICK HERE FOR A PRINTABLE OR WHITE BACKGROUND VERSION OF THIS ARTICLE

Researchers assessed the long term effect of Subthalamic nucleus Deep Brain Stimulation (DBS) on Parkinson's Disease. People with Parkinson's Disease were assessed before DBS and 1, 3, 5 years after DBS had begun. DBS involves the use of electrodes that are implanted into the brain and connected to a small electrical device called a pulse generator that can be externally programmed. DBS can reduce the need for L-dopa and related drugs, and reduce dyskinesia. For more information go to : Deep Brain Stimulation

As a result of DBS the quality of life improved by 58% after 3 years but gradually declined afterwards. Sleep, cognition, and emotion were mostly unchanged. After 5 years, when assessed without medication DBS improved Parkinson's Disease motor symptoms by 35%. However, after 5 years, when assessed with the simultaneous use of medication, motor symptoms were similar to those at the outset. L-dopa intake was reduced from 660mg to 310mg after 5 years. STN DBS can therefore improve Parkinson's Disease and reduce the need for L-dopa but there is a gradual decline and diminished efficacy after five years of use.

Reference : Chinese Medical Journal [2015] 128 (18) : 2433-2438 (L.L.Jiang, J.L.Liu, X.L. Fu, W.B.Xian, J.Gu, Y.M.Liu, J.Ye, J.Chen, H.Qian, S.H.Xu, Z.Pei, L.Chen) Complete abstract  In order to refer to this article on its own click here     

 

10th September  2015 - New research

DROXIDOPA - PARKINSON'S DISEASE CLINICAL TRIAL RESULTS

 CLICK HERE FOR A PRINTABLE OR WHITE BACKGROUND VERSION OF THIS ARTICLE

Although it normally has completely different uses, including orthostatic hypotension, the prodrug droxidopa has been found to reduce the symptoms of Parkinson's Disease. Droxidopa is a synthetic amino acid precursor. It can pass the blood brain barrier and form noradrenaline and adrenaline, which are derivatives of L-dopa and dopamine. Droxidopa is marketed as Northera. For more information go to : Droxidopa

The use of droxidopa in Parkinson's Disease was compared to the use of a placebo. The two groups were comparable in all respects. After two weeks and also nearly two months Parkinson's Disease symptoms scores were significantly different from the outset. Individual motor symptoms such as stiffness, resting tremor, and alternate hand motion were also significantly improved with the use of droxidopa, suggesting that droxidopa is effective in improving rigidity, tremor and alternate motion of hand.

Droxidopa was effective as symptomatic adjunct therapy, and significantly improved motor function and activities of daily living. On the way to forming noradrenaline and adrenaline, it must therefore have dopaminergic activity. 

Reference : Parkinsonism and Related Disorders [2015] Aug 21 [Epub ahead of print] (S. Zhao, R.Cheng, J.Zheng, Q.Li, J.Wang, W.Fan, L.Zhang, Y.Zhang, H.Li, S.Liu)  Complete abstract  In order to refer to this article on its own click here 

 

  GO TO AUGUST 2015  

  

  GO TO CURRENT NEWS  
 
 
©2006-2015 Viartis
 
mail@viartis.net